Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Phosphorylation of Serine 305 in Tau Inhibits Aggregation.

Strang KH, Sorrentino ZA, Riffe CJ, Gorion KM, Vijayaraghavan N, Golde TE, Giasson BI.

Neurosci Lett. 2018 Nov 10. pii: S0304-3940(18)30774-2. doi: 10.1016/j.neulet.2018.11.011. [Epub ahead of print]

PMID:
30423399
2.

High-affinity interactions and signal transduction between Aβ oligomers and TREM2.

Lessard CB, Malnik SL, Zhou Y, Ladd TB, Cruz PE, Ran Y, Mahan TE, Chakrabaty P, Holtzman DM, Ulrich JD, Colonna M, Golde TE.

EMBO Mol Med. 2018 Nov;10(11). pii: e9027. doi: 10.15252/emmm.201809027.

3.

Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau.

Audrain M, Haure-Mirande JV, Wang M, Kim SH, Fanutza T, Chakrabarty P, Fraser P, St George-Hyslop PH, Golde TE, Blitzer RD, Schadt EE, Zhang B, Ehrlich ME, Gandy S.

Mol Psychiatry. 2018 Oct 3. doi: 10.1038/s41380-018-0258-3. [Epub ahead of print]

PMID:
30283031
4.

Designing antibodies against LRRK2-targeted tau epitopes.

Hamm M, Ladd TB, Levites Y, Golde TE, Giasson BI, Lewis J.

PLoS One. 2018 Sep 27;13(9):e0204367. doi: 10.1371/journal.pone.0204367. eCollection 2018.

5.

Animal models of neurodegenerative diseases.

Dawson TM, Golde TE, Lagier-Tourenne C.

Nat Neurosci. 2018 Oct;21(10):1370-1379. doi: 10.1038/s41593-018-0236-8. Epub 2018 Sep 24. Review.

PMID:
30250265
6.

Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration.

Sorrentino ZA, Xia Y, Funk C, Riffe CJ, Rutherford NJ, Ceballos Diaz C, Sacino AN, Price ND, Golde TE, Giasson BI, Chakrabarty P.

Neurobiol Dis. 2018 Dec;120:98-106. doi: 10.1016/j.nbd.2018.09.005. Epub 2018 Sep 6.

PMID:
30195075
7.

TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease.

Chakrabarty P, Li A, Ladd TB, Strickland MR, Koller EJ, Burgess JD, Funk CC, Cruz PE, Allen M, Yaroshenko M, Wang X, Younkin C, Reddy J, Lohrer B, Mehrke L, Moore BD, Liu X, Ceballos-Diaz C, Rosario AM, Medway C, Janus C, Li HD, Dickson DW, Giasson BI, Price ND, Younkin SG, Ertekin-Taner N, Golde TE.

J Exp Med. 2018 Sep 3;215(9):2247-2264. doi: 10.1084/jem.20180484.

PMID:
30158114
8.

Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy.

Allen M, Wang X, Serie DJ, Strickland SL, Burgess JD, Koga S, Younkin CS, Nguyen TT, Malphrus KG, Lincoln SJ, Alamprese M, Zhu K, Chang R, Carrasquillo MM, Kouri N, Murray ME, Reddy JS, Funk C, Price ND, Golde TE, Younkin SG, Asmann YW, Crook JE, Dickson DW, Ertekin-Taner N.

Acta Neuropathol. 2018 Nov;136(5):709-727. doi: 10.1007/s00401-018-1900-5. Epub 2018 Aug 22.

9.

Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.

Hossain F, Majumder S, Ucar DA, Rodriguez PC, Golde TE, Minter LM, Osborne BA, Miele L.

Front Immunol. 2018 Jun 4;9:1288. doi: 10.3389/fimmu.2018.01288. eCollection 2018. Review.

10.

Challenges in Passive Immunization Strategies to Treat Parkinson Disease.

Manfredsson FP, Tansey MG, Golde TE.

JAMA Neurol. 2018 Oct 1;75(10):1180-1181. doi: 10.1001/jamaneurol.2018.0346. No abstract available.

PMID:
29913004
11.

Notch1 primes CD4 T cells for T helper type I differentiation through its early effects on miR-29.

Chandiran K, Lawlor R, Pannuti A, Perez GG, Srinivasan J, Golde TE, Miele L, Osborne BA, Minter LM.

Mol Immunol. 2018 Jul;99:191-198. doi: 10.1016/j.molimm.2018.05.002. Epub 2018 May 26.

12.

Novel monoclonal antibodies targeting the microtubule-binding domain of human tau.

Croft CL, Moore BD, Ran Y, Chakrabarty P, Levites Y, Golde TE, Giasson BI.

PLoS One. 2018 Apr 2;13(4):e0195211. doi: 10.1371/journal.pone.0195211. eCollection 2018.

13.

Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.

Strang KH, Croft CL, Sorrentino ZA, Chakrabarty P, Golde TE, Giasson BI.

J Biol Chem. 2018 Mar 23;293(12):4579. doi: 10.1074/jbc.AAC118.002657. No abstract available.

14.

Genome-wide pleiotropy analysis of neuropathological traits related to Alzheimer's disease.

Chung J, Zhang X, Allen M, Wang X, Ma Y, Beecham G, Montine TJ, Younkin SG, Dickson DW, Golde TE, Price ND, Ertekin-Taner N, Lunetta KL, Mez J; Alzheimer’s Disease Genetics Consortium, Mayeux R, Haines JL, Pericak-Vance MA, Schellenberg G, Jun GR, Farrer LA.

Alzheimers Res Ther. 2018 Feb 20;10(1):22. doi: 10.1186/s13195-018-0349-z.

15.

Correction to: Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer's disease resilience.

Ridge PG, Karch CM, Hsu S, Arano I, Teerlink CC, Ebbert MTW, Murcia JDG, Farnham JM, Damato AR, Allen M, Wang X, Harari O, Fernandez VM, Guerreiro R, Bras J, Hardy J, Munger R, Norton M, Sassi C, Singleton A, Younkin SG, Dickson DW, Golde TE, Price ND, Ertekin-Taner N, Cruchaga C, Goate AM, Corcoran C, Tschanz J, Cannon-Albright LA, Kauwe JSK; Alzheimer’s Disease Neuroimaging Initiative.

Genome Med. 2018 Jan 12;10(1):4. doi: 10.1186/s13073-018-0516-7.

16.

Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.

Strang KH, Croft CL, Sorrentino ZA, Chakrabarty P, Golde TE, Giasson BI.

J Biol Chem. 2018 Feb 16;293(7):2408-2421. doi: 10.1074/jbc.M117.815357. Epub 2017 Dec 19. Erratum in: J Biol Chem. 2018 Mar 23;293(12 ):4579.

PMID:
29259137
17.

Short Aβ peptides attenuate Aβ42 toxicity in vivo.

Moore BD, Martin J, de Mena L, Sanchez J, Cruz PE, Ceballos-Diaz C, Ladd TB, Ran Y, Levites Y, Kukar TL, Kurian JJ, McKenna R, Koo EH, Borchelt DR, Janus C, Rincon-Limas D, Fernandez-Funez P, Golde TE.

J Exp Med. 2018 Jan 2;215(1):283-301. doi: 10.1084/jem.20170600. Epub 2017 Dec 5.

18.

Ifngr1 and Stat1 mediated canonical Ifn-γ signaling drives nigrostriatal degeneration.

Strickland MR, Koller EJ, Deng DZ, Ceballos-Diaz C, Golde TE, Chakrabarty P.

Neurobiol Dis. 2018 Feb;110:133-141. doi: 10.1016/j.nbd.2017.11.007. Epub 2017 Nov 28.

PMID:
29196213
19.

Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer's disease resilience.

Ridge PG, Karch CM, Hsu S, Arano I, Teerlink CC, Ebbert MTW, Gonzalez Murcia JD, Farnham JM, Damato AR, Allen M, Wang X, Harari O, Fernandez VM, Guerreiro R, Bras J, Hardy J, Munger R, Norton M, Sassi C, Singleton A, Younkin SG, Dickson DW, Golde TE, Price ND, Ertekin-Taner N, Cruchaga C, Goate AM, Corcoran C, Tschanz J, Cannon-Albright LA, Kauwe JSK; Alzheimer’s Disease Neuroimaging Initiative.

Genome Med. 2017 Nov 29;9(1):100. doi: 10.1186/s13073-017-0486-1. Erratum in: Genome Med. 2018 Jan 12;10 (1):4.

20.

Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases.

Allen M, Wang X, Burgess JD, Watzlawik J, Serie DJ, Younkin CS, Nguyen T, Malphrus KG, Lincoln S, Carrasquillo MM, Ho C, Chakrabarty P, Strickland S, Murray ME, Swarup V, Geschwind DH, Seyfried NT, Dammer EB, Lah JJ, Levey AI, Golde TE, Funk C, Li H, Price ND, Petersen RC, Graff-Radford NR, Younkin SG, Dickson DW, Crook JR, Asmann YW, Ertekin-Taner N.

Alzheimers Dement. 2018 Mar;14(3):352-366. doi: 10.1016/j.jalz.2017.09.012. Epub 2017 Oct 31.

21.

A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies.

Dhillon JS, Riffe C, Moore BD, Ran Y, Chakrabarty P, Golde TE, Giasson BI.

PLoS One. 2017 Sep 14;12(9):e0184731. doi: 10.1371/journal.pone.0184731. eCollection 2017.

22.

Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.

Strang KH, Goodwin MS, Riffe C, Moore BD, Chakrabarty P, Levites Y, Golde TE, Giasson BI.

Acta Neuropathol Commun. 2017 Jul 31;5(1):58. doi: 10.1186/s40478-017-0458-0.

23.

Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.

Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER, Grenier-Boley B, Heilmann-Heimbach S, Chouraki V, Kuzma AB, Sleegers K, Vronskaya M, Ruiz A, Graham RR, Olaso R, Hoffmann P, Grove ML, Vardarajan BN, Hiltunen M, Nöthen MM, White CC, Hamilton-Nelson KL, Epelbaum J, Maier W, Choi SH, Beecham GW, Dulary C, Herms S, Smith AV, Funk CC, Derbois C, Forstner AJ, Ahmad S, Li H, Bacq D, Harold D, Satizabal CL, Valladares O, Squassina A, Thomas R, Brody JA, Qu L, Sánchez-Juan P, Morgan T, Wolters FJ, Zhao Y, Garcia FS, Denning N, Fornage M, Malamon J, Naranjo MCD, Majounie E, Mosley TH, Dombroski B, Wallon D, Lupton MK, Dupuis J, Whitehead P, Fratiglioni L, Medway C, Jian X, Mukherjee S, Keller L, Brown K, Lin H, Cantwell LB, Panza F, McGuinness B, Moreno-Grau S, Burgess JD, Solfrizzi V, Proitsi P, Adams HH, Allen M, Seripa D, Pastor P, Cupples LA, Price ND, Hannequin D, Frank-García A, Levy D, Chakrabarty P, Caffarra P, Giegling I, Beiser AS, Giedraitis V, Hampel H, Garcia ME, Wang X, Lannfelt L, Mecocci P, Eiriksdottir G, Crane PK, Pasquier F, Boccardi V, Henández I, Barber RC, Scherer M, Tarraga L, Adams PM, Leber M, Chen Y, Albert MS, Riedel-Heller S, Emilsson V, Beekly D, Braae A, Schmidt R, Blacker D, Masullo C, Schmidt H, Doody RS, Spalletta G, Longstreth WT Jr, Fairchild TJ, Bossù P, Lopez OL, Frosch MP, Sacchinelli E, Ghetti B, Yang Q, Huebinger RM, Jessen F, Li S, Kamboh MI, Morris J, Sotolongo-Grau O, Katz MJ, Corcoran C, Dunstan M, Braddel A, Thomas C, Meggy A, Marshall R, Gerrish A, Chapman J, Aguilar M, Taylor S, Hill M, Fairén MD, Hodges A, Vellas B, Soininen H, Kloszewska I, Daniilidou M, Uphill J, Patel Y, Hughes JT, Lord J, Turton J, Hartmann AM, Cecchetti R, Fenoglio C, Serpente M, Arcaro M, Caltagirone C, Orfei MD, Ciaramella A, Pichler S, Mayhaus M, Gu W, Lleó A, Fortea J, Blesa R, Barber IS, Brookes K, Cupidi C, Maletta RG, Carrell D, Sorbi S, Moebus S, Urbano M, Pilotto A, Kornhuber J, Bosco P, Todd S, Craig D, Johnston J, Gill M, Lawlor B, Lynch A, Fox NC, Hardy J; ARUK Consortium, Albin RL, Apostolova LG, Arnold SE, Asthana S, Atwood CS, Baldwin CT, Barnes LL, Barral S, Beach TG, Becker JT, Bigio EH, Bird TD, Boeve BF, Bowen JD, Boxer A, Burke JR, Burns JM, Buxbaum JD, Cairns NJ, Cao C, Carlson CS, Carlsson CM, Carney RM, Carrasquillo MM, Carroll SL, Diaz CC, Chui HC, Clark DG, Cribbs DH, Crocco EA, DeCarli C, Dick M, Duara R, Evans DA, Faber KM, Fallon KB, Fardo DW, Farlow MR, Ferris S, Foroud TM, Galasko DR, Gearing M, Geschwind DH, Gilbert JR, Graff-Radford NR, Green RC, Growdon JH, Hamilton RL, Harrell LE, Honig LS, Huentelman MJ, Hulette CM, Hyman BT, Jarvik GP, Abner E, Jin LW, Jun G, Karydas A, Kaye JA, Kim R, Kowall NW, Kramer JH, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lunetta KL, Lyketsos CG, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Morris JC, Murrell JR, Myers AJ, O'Bryant S, Olichney JM, Pankratz VS, Parisi JE, Paulson HL, Perry W, Peskind E, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reisberg B, Reitz C, Ringman JM, Roberson ED, Rogaeva E, Rosen HJ, Rosenberg RN, Sager MA, Saykin AJ, Schneider JA, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Swerdlow RH, Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Wilhelmsen KC, Williamson J, Wingo TS, Woltjer RL, Wright CB, Yu CE, Yu L, Garzia F, Golamaully F, Septier G, Engelborghs S, Vandenberghe R, De Deyn PP, Fernadez CM, Benito YA, Thonberg H, Forsell C, Lilius L, Kinhult-Stählbom A, Kilander L, Brundin R, Concari L, Helisalmi S, Koivisto AM, Haapasalo A, Dermecourt V, Fievet N, Hanon O, Dufouil C, Brice A, Ritchie K, Dubois B, Himali JJ, Keene CD, Tschanz J, Fitzpatrick AL, Kukull WA, Norton M, Aspelund T, Larson EB, Munger R, Rotter JI, Lipton RB, Bullido MJ, Hofman A, Montine TJ, Coto E, Boerwinkle E, Petersen RC, Alvarez V, Rivadeneira F, Reiman EM, Gallo M, O'Donnell CJ, Reisch JS, Bruni AC, Royall DR, Dichgans M, Sano M, Galimberti D, St George-Hyslop P, Scarpini E, Tsuang DW, Mancuso M, Bonuccelli U, Winslow AR, Daniele A, Wu CK; GERAD/PERADES, CHARGE, ADGC, EADI, Peters O, Nacmias B, Riemenschneider M, Heun R, Brayne C, Rubinsztein DC, Bras J, Guerreiro R, Al-Chalabi A, Shaw CE, Collinge J, Mann D, Tsolaki M, Clarimón J, Sussams R, Lovestone S, O'Donovan MC, Owen MJ, Behrens TW, Mead S, Goate AM, Uitterlinden AG, Holmes C, Cruchaga C, Ingelsson M, Bennett DA, Powell J, Golde TE, Graff C, De Jager PL, Morgan K, Ertekin-Taner N, Combarros O, Psaty BM, Passmore P, Younkin SG, Berr C, Gudnason V, Rujescu D, Dickson DW, Dartigues JF, DeStefano AL, Ortega-Cubero S, Hakonarson H, Campion D, Boada M, Kauwe JK, Farrer LA, Van Broeckhoven C, Ikram MA, Jones L, Haines JL, Tzourio C, Launer LJ, Escott-Price V, Mayeux R, Deleuze JF, Amin N, Holmans PA, Pericak-Vance MA, Amouyel P, van Duijn CM, Ramirez A, Wang LS, Lambert JC, Seshadri S, Williams J, Schellenberg GD.

Nat Genet. 2017 Sep;49(9):1373-1384. doi: 10.1038/ng.3916. Epub 2017 Jul 17.

24.

Targeting psychologic stress signaling pathways in Alzheimer's disease.

Futch HS, Croft CL, Truong VQ, Krause EG, Golde TE.

Mol Neurodegener. 2017 Jun 21;12(1):49. doi: 10.1186/s13024-017-0190-z. Review.

25.

Amyloid β peptides overexpression in retinal pigment epithelial cells via AAV-mediated gene transfer mimics AMD-like pathology in mice.

Prasad T, Zhu P, Verma A, Chakrabarty P, Rosario AM, Golde TE, Li Q.

Sci Rep. 2017 Jun 12;7(1):3222. doi: 10.1038/s41598-017-03397-2.

26.

Parkinson Disease and Autoimmune Disorders-What Can We Learn From Genome-wide Pleiotropy?

McFarland NR, McFarland KN, Golde TE.

JAMA Neurol. 2017 Jul 1;74(7):769-770. doi: 10.1001/jamaneurol.2017.0843. No abstract available.

PMID:
28586798
27.

Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity.

Sorrentino ZA, Brooks MMT, Hudson V 3rd, Rutherford NJ, Golde TE, Giasson BI, Chakrabarty P.

Mol Neurodegener. 2017 May 29;12(1):40. doi: 10.1186/s13024-017-0182-z.

28.

γ-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct.

Ran Y, Hossain F, Pannuti A, Lessard CB, Ladd GZ, Jung JI, Minter LM, Osborne BA, Miele L, Golde TE.

EMBO Mol Med. 2017 Jul;9(7):950-966. doi: 10.15252/emmm.201607265.

29.

A KCNC3 mutation causes a neurodevelopmental, non-progressive SCA13 subtype associated with dominant negative effects and aberrant EGFR trafficking.

Khare S, Nick JA, Zhang Y, Galeano K, Butler B, Khoshbouei H, Rayaprolu S, Hathorn T, Ranum LPW, Smithson L, Golde TE, Paucar M, Morse R, Raff M, Simon J, Nordenskjöld M, Wirdefeldt K, Rincon-Limas DE, Lewis J, Kaczmarek LK, Fernandez-Funez P, Nick HS, Waters MF.

PLoS One. 2017 May 3;12(5):e0173565. doi: 10.1371/journal.pone.0173565. eCollection 2017.

30.

Inflammatory pre-conditioning restricts the seeded induction of α-synuclein pathology in wild type mice.

Koller EJ, Brooks MM, Golde TE, Giasson BI, Chakrabarty P.

Mol Neurodegener. 2017 Jan 3;12(1):1. doi: 10.1186/s13024-016-0142-z.

31.

A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression.

Carrasquillo MM, Allen M, Burgess JD, Wang X, Strickland SL, Aryal S, Siuda J, Kachadoorian ML, Medway C, Younkin CS, Nair A, Wang C, Chanana P, Serie D, Nguyen T, Lincoln S, Malphrus KG, Morgan K, Golde TE, Price ND, White CC, De Jager PL, Bennett DA, Asmann YW, Crook JE, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N.

Alzheimers Dement. 2017 Jun;13(6):663-673. doi: 10.1016/j.jalz.2016.10.005. Epub 2016 Dec 8.

32.

Increased brain hemopexin levels improve outcomes after intracerebral hemorrhage.

Leclerc JL, Santiago-Moreno J, Dang A, Lampert AS, Cruz PE, Rosario AM, Golde TE, Doré S.

J Cereb Blood Flow Metab. 2018 Jun;38(6):1032-1046. doi: 10.1177/0271678X16679170. Epub 2016 Nov 19.

PMID:
27864463
33.

Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.

Golde TE.

J Neurochem. 2016 Oct;139 Suppl 2:224-236. doi: 10.1111/jnc.13583. Epub 2016 May 4. Review.

34.

Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases.

Allen M, Carrasquillo MM, Funk C, Heavner BD, Zou F, Younkin CS, Burgess JD, Chai HS, Crook J, Eddy JA, Li H, Logsdon B, Peters MA, Dang KK, Wang X, Serie D, Wang C, Nguyen T, Lincoln S, Malphrus K, Bisceglio G, Li M, Golde TE, Mangravite LM, Asmann Y, Price ND, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N.

Sci Data. 2016 Oct 11;3:160089. doi: 10.1038/sdata.2016.89.

35.

Holdase activity of secreted Hsp70 masks amyloid-β42 neurotoxicity in Drosophila.

Fernandez-Funez P, Sanchez-Garcia J, de Mena L, Zhang Y, Levites Y, Khare S, Golde TE, Rincon-Limas DE.

Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):E5212-21. doi: 10.1073/pnas.1608045113. Epub 2016 Aug 16.

36.

Deficiency in either COX-1 or COX-2 genes does not affect amyloid beta protein burden in amyloid precursor protein transgenic mice.

Park SA, Chevallier N, Tejwani K, Hung MM, Maruyama H, Golde TE, Koo EH.

Biochem Biophys Res Commun. 2016 Sep 9;478(1):286-292. doi: 10.1016/j.bbrc.2016.07.015. Epub 2016 Jul 15.

PMID:
27425247
37.

Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology.

Sacino AN, Brooks MM, Chakrabarty P, Saha K, Khoshbouei H, Golde TE, Giasson BI.

J Neurochem. 2017 Feb;140(4):662-678. doi: 10.1111/jnc.13743. Epub 2016 Aug 19.

38.

Alzheimer disease: Host immune defence, amyloid-β peptide and Alzheimer disease.

Golde TE.

Nat Rev Neurol. 2016 Aug;12(8):433-4. doi: 10.1038/nrneurol.2016.105. Epub 2016 Jul 15. Review. No abstract available.

PMID:
27418376
39.

Microglia-specific targeting by novel capsid-modified AAV6 vectors.

Rosario AM, Cruz PE, Ceballos-Diaz C, Strickland MR, Siemienski Z, Pardo M, Schob KL, Li A, Aslanidi GV, Srivastava A, Golde TE, Chakrabarty P.

Mol Ther Methods Clin Dev. 2016 Apr 13;3:16026. doi: 10.1038/mtm.2016.26. eCollection 2016.

40.

Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci.

Allen M, Burgess JD, Ballard T, Serie D, Wang X, Younkin CS, Sun Z, Kouri N, Baheti S, Wang C, Carrasquillo MM, Nguyen T, Lincoln S, Malphrus K, Murray M, Golde TE, Price ND, Younkin SG, Schellenberg GD, Asmann Y, Ordog T, Crook J, Dickson D, Ertekin-Taner N.

Acta Neuropathol. 2016 Aug;132(2):197-211. doi: 10.1007/s00401-016-1576-7. Epub 2016 Apr 26.

41.

γ-Secretase Modulators and APH1 Isoforms Modulate γ-Secretase Cleavage but Not Position of ε-Cleavage of the Amyloid Precursor Protein (APP).

Lessard CB, Cottrell BA, Maruyama H, Suresh S, Golde TE, Koo EH.

PLoS One. 2015 Dec 17;10(12):e0144758. doi: 10.1371/journal.pone.0144758. eCollection 2015.

42.

Re-Opening the Critical Window for Estrogen Therapy.

Bean LA, Kumar A, Rani A, Guidi M, Rosario AM, Cruz PE, Golde TE, Foster TC.

J Neurosci. 2015 Dec 9;35(49):16077-93. doi: 10.1523/JNEUROSCI.1890-15.2015.

43.

Murine Aβ over-production produces diffuse and compact Alzheimer-type amyloid deposits.

Xu G, Ran Y, Fromholt SE, Fu C, Yachnis AT, Golde TE, Borchelt DR.

Acta Neuropathol Commun. 2015 Nov 14;3:72. doi: 10.1186/s40478-015-0252-9.

44.

Non-prion-type transmission in A53T α-synuclein transgenic mice: a normal component of spinal homogenates from naïve non-transgenic mice induces robust α-synuclein pathology.

Sacino AN, Ayers JI, Brooks MM, Chakrabarty P, Hudson VJ 3rd, Howard JK, Golde TE, Giasson BI, Borchelt DR.

Acta Neuropathol. 2016 Jan;131(1):151-4. doi: 10.1007/s00401-015-1505-1. Epub 2015 Nov 5. No abstract available.

45.

Anti-Aβ single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's disease.

Fernandez-Funez P, Zhang Y, Sanchez-Garcia J, de Mena L, Khare S, Golde TE, Levites Y, Rincon-Limas DE.

Hum Mol Genet. 2015 Nov 1;24(21):6093-105. doi: 10.1093/hmg/ddv321. Epub 2015 Aug 7.

46.

Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans.

Ling IF, Golde TE, Galasko DR, Koo EH.

Alzheimers Res Ther. 2015 Aug 5;7(1):55. doi: 10.1186/s13195-015-0137-y. eCollection 2015.

47.

Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice.

Rutherford NJ, Sacino AN, Brooks M, Ceballos-Diaz C, Ladd TB, Howard JK, Golde TE, Giasson BI.

Mol Neurodegener. 2015 Jul 30;10:32. doi: 10.1186/s13024-015-0029-4.

48.

Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator.

Jung JI, Price AR, Ladd TB, Ran Y, Park HJ, Ceballos-Diaz C, Smithson LA, Hochhaus G, Tang Y, Akula R, Ba S, Koo EH, Shapiro G, Felsenstein KM, Golde TE.

Mol Neurodegener. 2015 Jul 14;10:29. doi: 10.1186/s13024-015-0021-z.

49.

IFN-γ promotes τ phosphorylation without affecting mature tangles.

Li A, Ceballos-Diaz C, DiNunno N, Levites Y, Cruz PE, Lewis J, Golde TE, Chakrabarty P.

FASEB J. 2015 Oct;29(10):4384-98. doi: 10.1096/fj.15-275834. Epub 2015 Jul 8.

50.

Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice.

Ceballos-Diaz C, Rosario AM, Park HJ, Chakrabarty P, Sacino A, Cruz PE, Siemienski Z, Lara N, Moran C, Ravelo N, Golde TE, McFarland NR.

Mol Neurodegener. 2015 Jul 8;10:25. doi: 10.1186/s13024-015-0026-7.

Supplemental Content

Loading ...
Support Center